Status:
COMPLETED
Efficacy and Tolerability of Flunarizine for the Treatment of Schizophrenia: Comparison With Haloperidol
Lead Sponsor:
Ambulatório de Bipolaridade
Collaborating Sponsors:
Stanley Medical Research Institute
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
Flunarizine is a calcium channel blocker traditionally used for the treatment of vertigo and migraine. It also has the mechanism of action associated with antipsychotic activity (D2 receptor blockade)...
Detailed Description
The main advantage of flunarizine over other D2 receptor blockers is its long half-life, so that it may be administered weekly or may delay relapse if medication is interrupted.
Eligibility Criteria
Inclusion
- DSM-IV schizophrenic or schizoaffective patients between 18 and 55 years old with a PANSS score above 45.
Exclusion
- Clinical disease
- Pregnancy
- Drug dependence (except for nicotine) in the past month and history of being refractory to at least 2 antipsychotics taken appropriately.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00740259
Start Date
September 1 2004
End Date
May 1 2007
Last Update
August 22 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universidade Federal de São Paulo
São Paulo, São Paulo, Brazil, 04023-900